A client comes to see me. She has been tired for three years. Her GP has run blood tests twice. Both times she was told everything was normal. She isn't anaemic. Her thyroid is fine. Her B12 is fine. She is simply — inexplicably, according to the tests — exhausted.
I look at her ferritin. It is 19 µg/L.
By the NHS reference range, this is normal. The conventional lower threshold for women is somewhere between 10 and 20 µg/L depending on which laboratory is running the test. She has cleared it. Not by much, but she has cleared it. Normal.
I have seen this particular version of "normal" more times than I can count. And I have watched what often happens when ferritin is brought up towards 50–100 µg/L over three to six months: for many people the fatigue lifts and the hair loss slows. That is my clinical experience, not a trial result — and the trial evidence that does exist, which I set out below, supports part of it.
There is peer-reviewed evidence that the conventional lower limit is set too low, and there is a legitimate counter-argument that deserves to be heard rather than dismissed. Both matter — because understanding the debate clarifies exactly what is being measured, what the number means, and what to do with it.
The debate — and why both sides have a point
In August 2026 the American Society of Hematology published its first evidence-based guideline on diagnosing iron deficiency, setting serum ferritin thresholds for specific populations and prioritising the diagnosis of iron deficiency whether or not anaemia is present (Blood Advances 2026). The move towards higher thresholds has split opinion.
Ferritin is an imperfect proxy for iron stores; bone marrow sampling is the gold standard, and some women are iron-replete below 30 µg/L. A higher threshold would classify a large share of menstruating women as iron-deficient. The evidence that treating non-anaemic iron deficiency relieves fatigue is limited to a small number of trials. We should treat symptomatic women who present for care, not screen healthy populations for a condition whose treatment benefits remain uncertain.
The conventional ferritin reference range was derived from populations that included iron-deficient individuals — making the lower limit methodologically circular. In one study of 62 anaemic patients, a ferritin of 30 µg/L or below had 92% sensitivity and 98% specificity for absent iron stores (Mast, Clin Chem 1998). Iron does far more than make haemoglobin. In an Irish cohort of first pregnancies, 84% of women had ferritin below 30 µg/L by 33 weeks (McCarthy 2024), and maternal ferritin below 30 µg/L at 15 weeks was associated with lower language and motor scores in the children at two years (McCarthy 2025, observational, n=189).
The sceptical position is making a valid argument about population screening and the risk of over-medicalisation. The screening position is making a valid argument about reference range methodology and the clinical consequences of under-recognition. They are, to a significant degree, arguing about different things.
"The problem is not that haematologists disagree about the threshold. The problem is that both camps are using a population-level framework to answer an individual clinical question."
The wrong question — and the right one
Both the sceptical and the screening positions are asking the same underlying question: at what ferritin level does a statistically significant proportion of the population develop iron deficiency? This is a reasonable question for screening policy. It is not the question a clinician should be asking about an individual patient.
"At what ferritin level does this person's biology function optimally?"
These are different questions, and they produce different answers. A ferritin of 22 µg/L may be entirely adequate for one person and functionally insufficient for another — depending on their iron demands, their metabolic rate, their thyroid status, their gut absorption capacity, their training load, and a dozen other variables that a single blood marker cannot capture in isolation.
This is precisely why ferritin should be read in context — alongside haemoglobin, serum iron, TIBC, transferrin saturation, and the full clinical picture — rather than as a standalone number with a pass/fail threshold attached.
What ferritin actually does — beyond haemoglobin
The sceptical position focuses heavily on anaemia as the endpoint — and fatigue in the absence of anaemia as an unreliable symptom. This framing misses something important. Iron's role in physiology extends far beyond red blood cell production, and the consequences of sub-optimal iron stores manifest in systems that are well upstream of the point at which haemoglobin drops.
Thyroid peroxidase, the enzyme that makes thyroid hormone, is a haem (iron-containing) enzyme. In observational studies iron-deficiency anaemia goes with lower T4 and T3 (Garofalo 2023). The enzymes that convert T4 to T3 are selenium enzymes, not iron enzymes, and no ferritin threshold for thyroid effects has been established.
Iron is an essential cofactor in the electron transport chain. Sub-optimal iron stores impair mitochondrial energy production — which is why the fatigue of iron insufficiency presents as cellular, not just haematological.
Tyrosine hydroxylase — the rate-limiting enzyme in dopamine synthesis — is iron-dependent. Low ferritin is associated with restless legs syndrome, the strongest symptom link in the literature. Links to motivation, concentration and mood are plausible and less well established.
Iron is required for lymphocyte proliferation and natural killer cell function. Sub-optimal iron stores impair immune response quality — not to a degree that shows up as recurrent infection necessarily, but enough to shift immune resilience and inflammatory thresholds.
Iron is required for myelination and neurotransmitter synthesis in the developing and adult brain. "Brain fog" in non-anaemic iron insufficiency has a neurological substrate, not merely a subjective one — and in some trials it has responded to iron repletion.
Hair follicles are among the most metabolically active tissues in the body and are among the first to suffer when iron stores are sub-optimal. Women with diffuse hair loss have lower average ferritin than women without it (Ahmed 2026 meta-analysis), though no specific threshold is validated and the benefit of iron without anaemia is unproven.
The point is not that every person with a ferritin of 22 µg/L will have all of these consequences. The point is that "normal" ferritin means the population average was not anaemic — it does not mean iron stores are adequate to support the full range of iron-dependent physiological processes.
The reference range problem — a methodological flaw worth understanding
The sceptical camp's strongest argument is about over-medicalisation. Their weakest argument, in my view, is their defence of the existing reference range.
Normal reference ranges in laboratory medicine are typically derived by taking a sample of "apparently healthy" individuals and identifying the central 95% of results. The 2.5th and 97.5th percentiles become the lower and upper limits of normal. This approach has a fundamental vulnerability: if the population used to derive the range contains a significant proportion of undiagnosed iron-deficient individuals — which, given global prevalence, is almost certain for ferritin — then the lower limit of normal is shifted downward by the very condition the range is trying to identify.
This is not a fringe argument. Several haematology researchers have made it explicitly: the lower ferritin reference range is methodologically circular. It was derived from a population that included iron-deficient people, making it an unreliable benchmark for identifying iron deficiency.
What the functional ranges actually say
The question I ask is not "is this ferritin normal?" but "at what ferritin level does this person's physiology work properly?" The table below shows how I read it. The lower bands rest on published evidence; the target band is my clinical target, and I label it as such.
| Ferritin Level | Conventional Status | Functional Assessment | Clinical Significance |
|---|---|---|---|
Below 12 µg/L |
Deficient | Severely depleted | Iron deficiency anaemia likely. Immediate clinical priority. |
12–30 µg/L |
Normal (low) | Insufficient | Iron deficiency by the evidence-based threshold (ferritin ≤30 µg/L), whether or not haemoglobin is normal. |
30–50 µg/L |
Normal | Borderline functional | Grey zone. In non-anaemic women with unexplained fatigue, iron improved fatigue only when ferritin was 50 µg/L or below (Verdon, BMJ 2003). |
50–100 µg/L |
Normal | My clinical target | My target for repletion, for men and women. The lower bound rests on the Verdon trial; the upper bound is a clinical choice, not a proven optimum. |
Above 150 µg/L |
Normal / High | Monitor carefully | Ferritin is an acute phase reactant — raised by inflammation. High ferritin without iron supplementation needs investigating, not celebrating; with a raised transferrin saturation it warrants a haemochromatosis check via the GP. |
What this means in practice
The sceptical camp is right that we shouldn't screen healthy asymptomatic populations with a single ferritin measurement and prescribe iron to everyone below 30. Iron is not a benign supplement — over-supplementation has genuine risks, particularly for those with haemochromatosis or inflammatory conditions where ferritin elevation reflects pathology rather than sufficiency.
The screening camp is right that we've been missing real pathology in real people for decades, using a reference range that was built with a methodological flaw at its foundation, in a population where iron deficiency is the most prevalent micronutrient deficiency globally.
The clinical reality sits between both positions — and it requires individual assessment rather than population policy.
When I see ferritin in a comprehensive blood chemistry panel, I look at it alongside haemoglobin, haematocrit, MCV, serum iron, TIBC, and transferrin saturation. I look at the clinical picture — the fatigue, the hair loss, the cold intolerance, the cognitive symptoms. I look at the thyroid panel, because low ferritin and apparent hypothyroid symptoms often appear together in people whose TSH is technically within range. I look at the OAT for mitochondrial function markers. I look at the full picture, not the single number.
If a client's ferritin is 22 µg/L and they have fatigue, hair loss, low-normal thyroid numbers, and a clinical history consistent with iron insufficiency, I don't reassure them that their ferritin is normal and send them on their way. I address the iron stores — through diet, through targeted supplementation where indicated, and through retesting to confirm restoration rather than assuming it.
If their ferritin is 22 µg/L and they have no symptoms, good energy, no hair loss, and their thyroid is converting well, I note it, monitor it, and don't medicalise it.
That is the distinction the population debate cannot make. The individual clinical assessment can.
The deeper issue — what "normal" has come to mean
The ferritin debate is a specific instance of a larger problem in conventional laboratory medicine. Reference ranges tell us what is statistically common. They were never designed to tell us what is physiologically optimal. When we use them as though they are the same thing, we end up in the position of reassuring people that a result is normal when what we actually mean is that it falls within the central 95% of a population sample — a sample that may itself have been iron-deficient, vitamin D-insufficient, or metabolically compromised when the range was set.
The question that conventional ranges ask is: how does this compare to the average? The question functional medicine asks is: does this level support optimal physiology in this person? They are different questions. They produce different answers. And the gap between them is often where chronic, complex, unexplained symptoms live.
A ferritin of 19 µg/L is normal. But it is not necessarily optimal. For many people — particularly women of reproductive age, people with low-normal thyroid numbers, people with unexplained fatigue and hair loss — it is not remotely close to optimal. And the fact that it clears a population-derived reference range should not be the end of the clinical conversation. It should be the beginning.
Ferritin is on every TDG blood chemistry panel
Interpreted alongside serum iron, TIBC, transferrin saturation, and the full thyroid panel. If your ferritin is "normal" but your thyroid symptoms, fatigue, or hair loss suggest something is being missed, that is exactly the gap a comprehensive functional blood chemistry is designed to close.
See the TDG Five-Test Programme →